Optimal management of testicular cancer: from self-examination to treatment of advanced disease

References

• Richie JP. Advances in the diagnosis and treatment of testicular cancer. Cancer Invest. 1993;11:670–675.
   PubMed Web of Science ®Google Scholar
• Sandeman TF. Symptoms and early management of germinal tumors of the testis. Med J Aust. 1979;2:281–284.
   PubMed Web of Science ®Google Scholar
• Patton JF, Hewitt CB, Mallis N. Diagnosis and treatment of tumors of the testis. J Am Med Assoc. 1959;171:2194–2198.
   PubMed Web of Science ®Google Scholar
• Robson CJ, Bruce AW, Charbonneau J. Testicular tumors: a collective review from the Canadian Academy of Urological Surgeons. J Urol. 1965;94:440–444.
   PubMed Web of Science ®Google Scholar
• Bosl GJ, Vogelzang NJ, Goldman A, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet. 1981;2:970–973.
   PubMed Web of Science ®Google Scholar
• Thornhill JA, Fennelly JJ, Kelly DG, et al. Patients’ delay in the presentation of testis cancer in Ireland. Br J Urol. 1987;59:447–451.
   PubMedGoogle Scholar
• Honig SC, Lipshultz LI, Jarow J. Significant medical pathology uncovered by a comprehensive male infertility evaluation. Fertil Steril. 1994;62:1028–1034.
   PubMed Web of Science ®Google Scholar
• Jacobsen R, Bostofte E, Engholm G, et al. Risk of testicular cancer in men with abnormal semen characteristics: cohort study. BMJ. 2000;321:789–792.
   PubMed Web of Science ®Google Scholar
• Petersen PM, Skakkebaek NE, Vistisen K, Rorth M, Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol. 1999;17:941–947.
   PubMed Web of Science ®Google Scholar
• Moul JW Timely diagnosis of testicular cancer. Urol Clin North Am. 2007;34:109–117.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP Diagnostic delay in testicular cancer: an analytic chimaera or a worthy goal? Eur Urol. 2007;52:1566–1568.
   PubMed Web of Science ®Google Scholar
• Moul JW, Paulson DF, Dodge RK, Walther PJ. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol. 1990;143:520–523.
   PubMed Web of Science ®Google Scholar
• Vasudev NS, Joffe JK, Cooke C, Richards F, Jones WG. Delay in the diagnosis of testicular tumours – changes over the past 18 years. Br J Gen Pract. 2004;54:595–597.
   PubMed Web of Science ®Google Scholar
• Lassmann J, Wille A, Wiechen K, et al. Diagnostic difficulties before definitive treatment of an extragonadal retroperitoneal germ cell tumor. Urology. 2001;58:281–281.
   PubMedGoogle Scholar
• Moul JW, Moellman JR. Unnecessary mastectomy for gynecomastia in testicular cancer patient. Mil Med. 1992;157:433–4434.
   PubMed Web of Science ®Google Scholar
• Post GJ, Belis JA. Delayed presentation of testicular tumors. South Med J. 1980;73:33–35.
   PubMed Web of Science ®Google Scholar
• Prout GR Jr, Griffin PP. Testicular tumors: delay in diagnosis and influence on survival. Am Fam Physician 1984;29:205–209.
   PubMed Web of Science ®Google Scholar
• Fleming I, Cooper J, Henson D, et al. AJCC Cancer Staging Manual, 5 ed. New York, NY: Lippincott-Raven, 1997.
   Google Scholar
• International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol. 1997;15:594–603.
   PubMedGoogle Scholar
• Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol. 2008;53:497–513.
   PubMed Web of Science ®Google Scholar
• Classen J, Schmidberger H, Meisner C, et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG). Br J Cancer. 2004;90:2305–2311.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Aass N, Ous S, et al. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol. 1989;142:1239–1242.
   PubMed Web of Science ®Google Scholar
• Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol. 1995;13:2255–2262.
   PubMed Web of Science ®Google Scholar
• Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23:1200–1208.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Stenning SP, Gerl A, et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumors. Br J Cancer. 1999;80:1392–1399.
   PubMed Web of Science ®Google Scholar
• Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;366:293–300.
   PubMed Web of Science ®Google Scholar
• Peckham MJ, McElwain TJ. Radiotherapy of testicular tumors. Proc R Soc Med. 1974;67:300–303.
   PubMedGoogle Scholar
• Classen J, Schmidberger H, Meisner C, et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21:1101–1106.
   PubMed Web of Science ®Google Scholar
• Puc HS, Heelan R, Mazumdar M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center. J Clin Oncol. 1996;14:454–460.
   PubMed Web of Science ®Google Scholar
• De Santis M, Becherer A, Bokemeyer C, et al. 2–18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol. 2004;22:1034–1039.
   PubMed Web of Science ®Google Scholar
• Lewis DA, Tann M, Kesler K, et al. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol. 2006;24:e54–e55.
   PubMed Web of Science ®Google Scholar
• Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;2:294–298.
   PubMed Web of Science ®Google Scholar
• Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol. 1992;10:1762–1768.
   Google Scholar
• Vergouwe Y, Steyerberg EW, de Wit R, et al. External validity of a predic – tion rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients. Br J Cancer. 2003;88:843–847.
   PubMed Web of Science ®Google Scholar
• Kakiashvili DM, Zuniga A, Jewett MA. High risk NSGCT: case for surveillance. World J Urol. 2009;27:441–447.
   PubMed Web of Science ®Google Scholar
• Witthuhn R, Geeter PD, Albers P. Retroperitoneal residual tumor (RTR) resection for testicular cancer-template instead of full bilateral resection. (Abstract) Journal of Urology. 2007:177–331.
   Google Scholar
• Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;25:1310–1315.
   PubMed Web of Science ®Google Scholar
• Divrik RT, Akdogan B, Ozen H, Zorlu F Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified? J Urol. 2006;176:1424–1429.
   PubMed Web of Science ®Google Scholar
• Ernst DS, Brasher P, Venner PM, et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centers. Can J Urol. 2005;12:2575–2580.
   PubMedGoogle Scholar
• Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumors: 17 years’ experience in a national study in New Zealand. BJU Int. 1999;83:76–82.
   PubMed Web of Science ®Google Scholar
• Westermann DH, Studer UE. High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World J Urol. 2009;27:455–461.
   PubMed Web of Science ®Google Scholar
• Brydoy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009;101:1682–1695.
   PubMedGoogle Scholar
• Hartlapp JH, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl. 1987;10:277–284.
   PubMedGoogle Scholar
• Rabbani F, Sheinfeld J, Farivar-Mohseni H, et al. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol. 2001;19:2020–2025.
   PubMed Web of Science ®Google Scholar
• Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol. 1991;9:1393–1396.
   PubMed Web of Science ®Google Scholar
• Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med. 1987;317:1433–1438.
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol. 1993;149:237–243.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Hermans BP, Heilman DK, et al. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma – predominant testis cancer. J Clin Oncol. 2000;18:358–362.
   Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, Cheng L, Donohue JP. Does the histology of nodal metastasis predict systemic relapse after retroperitoneal lymph node dissection in pathological stage B1 germ cell tumors? J Urol. 2005;174:1287–1290.
   PubMed Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, Cheng L, Ulbright TM, Donohue JP. Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor. J Urol. 2005;174:143–145.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol. 1995;13:2700–2704.
   PubMed Web of Science ®Google Scholar
• Behnia M, Foster R, Einhorn LH, Donohue J, Nichols CR. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer. 2000;36:472–475.
   Google Scholar
• Foster RS, McNulty A, Rubin LR, et al. Fertility considerations in nerve-sparing retroperitoneal lymph-node dissection. World J Urol. 1994;12:136–138.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169:1710–1714.
   PubMed Web of Science ®Google Scholar
• Jewett MA. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am. 1990;17:449–456.
   PubMed Web of Science ®Google Scholar
• Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of primary retroperitoneal lymph node dissection. J Urol. 1994;152:424–427.
   PubMed Web of Science ®Google Scholar
• Beck SDW, Peterson MD, Bihrle R, Donohue JP, Foster RS. Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. J Urol. 2007;178:504–506.
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965–1989) using routine primary retroperitoneal lymph node dissection. Eur J Cancer. 1995;31A:1599–1604.
   Google Scholar
• Culine S, Kerbrat P, Kramar A, et al. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol. 2007;18:917–924.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Loehrer PJ, et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989;7:387–391
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Nichols CJ, Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256.
   PubMed Web of Science ®Google Scholar
• Ehrlich Y, Yossepowitch O, Kedar D, Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int. 2006;97:1221–1224.
   PubMed Web of Science ®Google Scholar
• Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol. 1997;15:1455–1464.
   PubMed Web of Science ®Google Scholar
• Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005;23:6149–6156.
   PubMed Web of Science ®Google Scholar
• Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol. 1993;11:324–329.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413–2418.
   PubMed Web of Science ®Google Scholar
• Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007;357:340–348.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J, et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol. 2000;18:1173–1180.
   PubMed Web of Science ®Google Scholar
• Rick O, Beyer J, Kingreen D, et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer. 1998;34:1883–1888.
   PubMed Web of Science ®Google Scholar
• Donohue JP, Foster RS. Management of retroperitoneal recurrences: Seminoma and Nonseminoma. In: Urologic Clinics of North America, Resnick M (ed), 1994;21:761–772.
   Google Scholar
• Loehrer PJ Sr, Hui S, Clark S, et al. Teratoma following cisplatin-based combination chemotherapy for nonseminomatous germ cell tumors: a clinicopathological correlation. J Urol. 1986;135:1183–1189.
   PubMed Web of Science ®Google Scholar
• Tait D, Peckham MJ, Hendry WF, Goldstraw P. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984;50:601–609.
   PubMed Web of Science ®Google Scholar
• Stenning SP, Parkinson MC, Fisher C, et al. Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumor Working Party. Cancer. 1998;83:1409–1419.
   Google Scholar
• Beck SDW, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Long term clinical outcomes for patients with high volume retroperitoneal teratoma undergoing post chemotherapy surgery. Journal of Urology. 2007;177:331, Abstract.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy – results from an international study group. J Clin Oncol. 2001;19:2647–2657.
   PubMed Web of Science ®Google Scholar
• Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol. 1998;16:65–71.
   PubMedGoogle Scholar
• McKiernan JM, Motzer RJ, Bajorin DF, et al. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. Urology. 2003;62:732–736.
   PubMed Web of Science ®Google Scholar
• George DW, Foster RS, Hromas RA, et al. Update on late relapse of germ cell tumor: a clinical and molecular analysis. J Clin Oncol. 2003;21:113–122.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173:824–829.
   PubMed Web of Science ®Google Scholar